TickerGuard
Buy Day today: Poor (52) Mixed market breadth · today: Core PCE (August) ≈
ALT

Altimmune Inc

Healthcare · Biotechnology

3.00$ -4.7% vs. previous close Closing price · As of: Sep 24, 2026

Statements

Balance Sheet

Altimmune Inc (ALT) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 527 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios
Annual Quarterly
Amounts Change % Common size %
Last 12 Full history
Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet ALT
Line item Q3 16 Q4 16 Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 Q3 19 Q4 19 Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
141 225 21 91 74 63 63 52 53 55 55 62 56 54 54 103 233 245 264 257 237 219 206 210 225 207 187 183 167 211 188 173 148 139 157 190 218 280 336 527
138 222 18 17 26 23 23 12 12 39 39 46 42 39 40 88 218 230 245 239 218 204 191 196 211 193 173 170 153 210 188 171 146 137 155 188 217 278 335 335
69 154 16 8.4 17 8.8 8.8 4.2 8.0 34 34 42 11 9.0 11 65 143 116 150 174 175 190 180 136 127 111 105 102 87 135 79 57 31 37 49 183 61 44 98 63
136 221 16 8.4 17 8.8 8.8 4.2 8.0 34 34 42 39 37 33 80 207 216 227 218 200 190 180 185 202 185 166 160 141 198 182 165 139 132 150 183 211 273 332 326
1.6 1.2 2.0 7.1 8.0 10 10 6.4 3.5 4.5 4.5 3.7 2.0 1.7 6.0 6.7 10 12 13 11 11 5.8 6.1 6.1 4.4 2.5 3.4 3.7 4.5 4.9 2.6 3.0 3.3 3.1 2.5 0.9 0.1 1.7 0.3 3.3
0.0 0.0 0.0 0.0 0.0 0.0 3.5 0.6 0.0 – 0.0 – – 0.0 – 0.0 – 0.0 0.0 0.0 – -5.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 – 0.0 – 0.0 – – – – – – –
0.2 0.1 0.1 0.3 0.3 0.6 1.4 1.5 1.4 1.3 1.3 1.2 1.2 1.1 1.1 1.7 1.0 1.1 5.2 4.8 4.7 1.4 1.3 1.2 1.2 1.7 1.0 0.9 1.2 – – – – – – – – – – –
20 19 19 35 9.3 0.0 0.0 0.0 0.0 – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – –
16 15 15 38 39 39 39 38 38 14 14 14 13 13 13 13 13 13 13 13 13 12 12 12 12 12 12 12 12 – – – – – – – – – – –
4.2 205 2.7 15 26 14 14 16 13 6.4 6.4 5.8 7.0 8.5 12 23 33 19 18 16 28 20 21 15 20 22 19 16 16 17 15 21 14 16 15 29 33 55 52 53
3.7 205 2.2 5.5 4.2 3.8 3.8 7.1 8.3 4.5 4.5 3.5 2.5 3.9 6.0 4.9 6.3 12 9.8 9.1 19 18 19 14 16 17 15 11 12 12 11 15 8.6 10 9.8 9.2 13 15 11 13
1.2 0.5 – 0.0 0.0 0.0 0.0 1.3 1.5 0.1 0.1 0.4 0.4 0.3 0.3 0.9 0.3 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.5 0.5 0.5 0.5 0.5 0.5 0.3 0.3 0.3 0.2 0.2 0.2 0.3 0.3 –
0.6 2.0 0.8 1.1 0.5 3.8 0.1 0.2 0.2 4.5 0.4 0.3 0.0 0.0 0.9 0.2 0.9 0.6 0.4 1.4 0.0 2.0 2.2 2.9 1.4 4.8 5.2 4.0 3.0 2.1 3.8 2.7 1.1 0.2 1.1 0.9 4.8 2.7 1.5 1.3
0.0 0.5 0.0 0.6 4.6 4.6 3.8 4.3 1.9 1.9 2.3 2.2 1.8 1.9 1.8 1.7 1.9 1.8 1.7 1.6 1.6 1.5 1.7 1.5 4.5 – 4.4 4.2 – – – – – – – 14 14 34 35 35
136 19 18 76 49 39 49 36 40 48 48 56 49 46 42 80 200 226 246 241 209 199 185 195 205 185 168 168 150 194 173 153 133 124 142 161 186 225 284 474
-108 -30 -32 -39 -69 -78 -78 -90 -92 -117 -117 -122 -133 -137 -141 -158 -176 -186 -211 -236 -269 -293 -313 -333 -356 -378 -398 -414 -435 -466 -491 -515 -538 -561 -581 -603 -622 -649 -672 -695
0.2 0.2 0.2 0.4 0.5 0.7 0.7 1.0 1.3 9.5 9.5 13 15 15 15 18 33 39 39 41 41 42 44 48 49 50 50 51 54 58 71 71 71 71 76 81 89 101 124 185

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?